Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $113
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $108 to $113.
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $108 to $113.